Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD). | Open Access Rheumatol;10: 151-160, 2018. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD).

Acar, Mustafa; Juneja, Prabhjot; Handel, Malcolm.

Affiliation

Acar M; Janssen-Cilag Pty Ltd, Sydney, NSW, Australia, macar@its.jnj.com.
Juneja P; Prospection Pty Ltd., Sydney, NSW, Australia.
Handel M; Janssen-Cilag Pty Ltd, Sydney, NSW, Australia, macar@its.jnj.com.

Open Access Rheumatol ; 10: 151-160, 2018.

Article in En | MEDLINE | ID: mdl-30568519

Key words

ankylosing spondylitis; arthritis; psoriatic; rheumatoid arthritis; treatment persistence; tumor necrosis factor inhibitors

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies / Prognostic_studies Language: En Journal: Open Access Rheumatol Year: 2018 Document type: Article Country of publication: New Zealand

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies / Prognostic_studies Language: En Journal: Open Access Rheumatol Year: 2018 Document type: Article Country of publication: New Zealand